Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny study asks: does aspirin work in patients with low platelets?

NCT ID NCT04912505

First seen Jan 07, 2026 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This study looked at how well a daily low-dose aspirin works in people who have both immune thrombocytopenia (low platelets) and heart disease. Only 4 adults took part. Researchers measured platelet function after aspirin to see if the standard dose is enough to prevent blood clots. The study is complete, but the small size means the findings are very limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Toulouse Hospital

    Toulouse, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Aspirin

What this could lead to

If successful, this could help doctors understand if standard aspirin dosing is enough to protect against blood clots in people with immune thrombocytopenia.

What could go wrong

This was a very small, early-phase study with only 4 participants, so results may not apply to everyone. The study is already completed, and no new treatment is being tested.

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.